Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Treasury Shares: 2020-2025

Historic Treasury Shares for Aclaris Therapeutics (ACRS) over the last 6 years, with Sep 2025 value amounting to $3.1 million.

  • Aclaris Therapeutics' Treasury Shares rose 0.87% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 0.87%. This contributed to the annual value of $2.1 million for FY2024, which is 37.73% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Treasury Shares is $3.1 million, which was down 1.15% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Treasury Shares registered a high of $3.2 million during Q1 2025, and its lowest value of $1.4 million during Q1 2022.
  • In the last 3 years, Aclaris Therapeutics' Treasury Shares had a median value of $3.1 million in 2024 and averaged $2.5 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Treasury Shares skyrocketed by 5,055.33% in 2021, and later tumbled by 41.55% in 2022.
  • Aclaris Therapeutics' Treasury Shares (Quarterly) stood at $1.5 million in 2021, then grew by 2.09% to $1.5 million in 2022, then increased by 0.08% to $1.5 million in 2023, then spiked by 37.73% to $2.1 million in 2024, then climbed by 0.87% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.1 million for Q2 2025, and $3.2 million during Q1 2025.